METTL3 and metabolic syndrome: It has also been shown that Mettl3-IGFBP2-mediated changes in m6A levels increase HDAC1 mRNA stability to affect FGF21 expression, leading to liver injury and insulin resistance caused by hepatic steatosis and ultimately the development of metabolic syndrome (Chen et al., 2023).